Annovis Bio, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone fourth-quarter report. Annovis is a clinical-stage biotechnology company with no approved products and no product-sales revenue.
Business context and development
The company’s lead candidate, ANVS401, is an oral drug in development for Alzheimer’s disease (AD), Parkinson’s disease (PD), and AD associated with Down syndrome (AD-DS). The company is also developing ANVS405 for acute brain injury and ANVS301 for advanced AD; neither is an approved product.
- Two double-blind, placebo-controlled Phase 2a studies of ANVS401 were underway: an ADCS study in early AD and a separate AD/PD study. The latter began treating patients in August 2020 and was planned for 14 AD and 54 PD patients.
- An NIH-funded toxicology grant supported long-term rat and dog studies; those studies were substantially completed by year-end.
Financial results and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $3.05 million | $0.78 million |
| General and administrative expense | $3.59 million | $0.83 million |
| Total operating expenses | $6.64 million | $1.61 million |
| Grant income | $1.16 million | $0.74 million |
| Net loss | $5.46 million | $0.99 million |
| Basic and diluted loss per share | $0.87 | $3.51 |
| Net cash used in operating activities | $3.97 million | $0.48 million |
At December 31, 2020, cash and cash equivalents were $8.07 million, current assets were $8.12 million, current liabilities were $0.58 million, and stockholders’ equity was $7.54 million. The company reported no outstanding convertible-note debt at year-end; the $530,000 of notes outstanding in 2019 converted into common shares at the IPO. No product gross margin or operating margin is reported because the company had no product sales.
The January 2020 IPO generated approximately $12.03 million in net proceeds. Financing activities provided $12.04 million in cash during 2020. Management said available cash was expected to fund operations and capital needs for at least 12 months; elsewhere the filing estimated funding through at least March 31, 2022. The company had no committed external funding source.
Material changes versus FY2019
- Net loss increased to $5.46 million from $0.99 million, as operating expenses rose substantially. R&D expense increased mainly with the AD/PD trial; G&A rose in part due to higher stock-based compensation, personnel and insurance costs, and public-company expenses.
- Cash increased from $1,858 to $8.07 million, primarily due to IPO proceeds. Operating cash use also increased, reflecting clinical development spending and payments of prior-year liabilities.
- Preferred stock and convertible notes converted to common stock in connection with the IPO; year-end long-term debt and derivative liability were zero.
Outlook, risks and unusual items
- Management expected higher R&D and G&A spending in 2021 and subsequent years, including continued Phase 2 work and planning for a Phase 3 AD-DS study. The company’s stated goal was to conduct pivotal studies in AD-DS and PD and file one or two NDAs by the end of 2024; these are plans, not assured outcomes.
- The filing reported preliminary human proof-of-concept observations from only four MCI patients treated for 10 days. Biomarker reductions were reported, but the small study does not establish clinical efficacy; the alpha-synuclein observation was described as unpublished and not statistically significant.
- COVID-19 temporarily halted new enrollment at ADCS and delayed opening AD/PD trial sites. Sites had reopened, but further disruption remained uncertain.
- Key risks include continued losses and need for additional capital; clinical, regulatory and commercialization uncertainty; reliance on third-party manufacturers and clinical organizations; and dependence on ANVS401. The company also disclosed that licensed core patents expire between 2022 and 2026, making the scope and success of newer patent applications important.
- The filing reported no material pending legal proceedings and no off-balance-sheet arrangements. Management assessed disclosure controls and internal control over financial reporting as effective; the auditor did not provide an internal-control attestation.
Important facts for investors to verify
- Current cash runway, subsequent financing needs, and whether development plans can be funded without substantial dilution or partnering.
- Final, controlled Phase 2a results—including safety, biomarker, cognitive and functional outcomes—and how they compare with the limited four-patient proof-of-concept observations.
- Actual trial enrollment, timing and regulatory requirements for any Phase 3 studies, particularly the proposed AD-DS and PD programs.
- Status, scope and duration of patent protection for ANVS401, along with obligations and milestone payments under the Horizon license.
- Whether the projected trial timelines remain achievable given COVID-related disruption, patient recruitment, manufacturing capacity and third-party dependencies.